7 completed, 7 terminated, 7 withdrawn, 1 recruiting. 23 Phase 2, 10 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 7, Terminated 7, Withdrawn 7, Recruiting 1, Unknown 1 |
| Phase 1 | 10 | Withdrawn 6, Completed 2, Terminated 2 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Lovaza: new trials by email Literature Review of Lovaza trials Research Report on Lovaza
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g - Postoperative Delirium | Phase 2 | Terminated | University of Missouri-Columbia | 1 | 2026-03-03 | 2026-05-11 |
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters - Breast Atypical Hyperplasia, Breast Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-07-28 | 2026-11-19 |
| Immunonutrition for Diabetic Foot Ulcers Lovaza, L-Arginine Powder, Vitamin C - Diabetes Mellitus, Diabetic Peripheral Neuropathy | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 1 | 2023-02-08 | 2024-12-27 |
| Altering Lipids for Tolerance of Aromatase Inhibitor Therapy Omega-3 fatty acid supplement - Breast Cancer | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 77 | 2020-07-28 | 2026-05-06 |
| Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) Omega-3 fatty acid ethyl esters (2 gram) - Colorectal Cancer, Lynch Syndrome | Phase 2 | Unknown | University of Kansas Medical Center | 21 | 2019-02-06 | 2023-06-01 |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC avelumab, bevacizumab, capecitabine - Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-01 | 2025-02-21 | |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors avelumab, Bevacizumab, Capecitabine - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-02-01 | 2025-02-21 | |
| QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Aldoxorubicin HCl, ALT-803, ETBX-011 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 4 | 2017-12-28 | 2024-05-22 |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy avelumab, bevacizumab, capecitabine - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL avelumab, bevacizumab, capecitabine - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy avelumab, bevacizumab, capecitabine - Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy ALT-803, ETBX-011, GI-4000 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 6 | 2017-11-06 | 2024-12-12 |
| Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury Omega 3 fatty acid, Safflower seed oil - TBI | Phase 2 | Withdrawn | University of Pennsylvania | 2017-01-01 | 2022-10-13 | |
| Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention Eicosapentanoic acid and docosahexanoic acid, Oleic Acid - Colorectal Adenomatous Polyps | Phase 2 | Completed | Vanderbilt University | 141 | 2013-02-04 | 2018-06-08 |
| Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia Lovaza - Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Sanford Research | 15 | 2009-09-01 | 2021-10-20 |
| Fish Oil Study for High Triglyceride Levels in Children Omega-3-acid ethyl esters, Placebo - Hypertriglyceridemia | Phase 2 / Phase 3 | Completed | Babu Balagopal | 42 | 2009-07-01 | 2022-11-08 |
| Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors Omega-3 Fatty Acid - Breast Cancer | Phase 2 | Terminated | Columbia University | 10 | 2009-06-01 | 2014-07-23 |
| Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease Lovaza, Placebo - HIV Infections, Heart Disease | Phase 2 | Completed | University Hospitals Cleveland Medical Center | 35 | 2009-04-01 | 2015-01-07 |
| The Effects of Omega-3 Fatty Acids on Aspirin Resistance Aspirin, Lovaza, Both Aspirin and Lovaza - Increased Drug Resistance | Phase 1 / Phase 2 | Completed | University of Rochester | 27 | 2008-11-01 | 2012-11-06 |
Showing 20 of 23. Sign in to see all of them.
Breast Neoplasms (3) · Colorectal Neoplasms (3) · Hypertriglyceridemia (3) · Cardiovascular Diseases (2) · Pancreatic Neoplasms (2) · Body Weight (1) · Breast Carcinoma In Situ (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Delirium (1) · Diabetes Mellitus (1) · Diabetic Foot (1) · Emergence Delirium (1)
ImmunityBio, Inc. (8) · Babu Balagopal (1) · Boston Children's Hospital (1) · Columbia University (1) · Invitrox (1) · National Cancer Institute (NCI) (1) · Prisma Health-Midlands (1) · Sanford Research (1) · University Hospitals Cleveland Medical Center (1) · University of Illinois at Chicago (1) · University of Kansas Medical Center (1) · University of Michigan Rogel Cancer Center (1) · University of Missouri-Columbia (1) · University of Pennsylvania (1) · University of Rochester (1)
United States (16)
Anwaar Saeed, MD (1) · Dawn Hershman, MD (1) · Grace McComsey, MD (1) · Gregory C Shearer, PhD (1) · Harvey J Murff, MD, MPH (1) · J. Benjamin Jackson, MD (1) · Lauren Nye (1) · Lynn Henry, MD, PhD (1) · Mauricio Cohen, MD (1) · Quinn Johnson, MD (1) · Ramon Diaz-Arrastia, MD, PhD (1) · Robert C Block, MD, MPH (1) · Samuel Gidding, MD (1) · Sara DeFerranti, MD (1) · Scott Cotler, M.D. (1)
PMID 21621252, PMID 21870979, PMID 25393536, PMID 34291724
P30CA046592 (1), R01CA160938 (1), UG1CA242632 (1)